SCHEDULE 13G: BlackRock Discloses 5.1% Passive Stake in Artiva Biotherapeutics

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.1% beneficial ownership stake in Artiva Biotherapeutics, Inc. as of March 31, 2025, held in the ordinary course of business.

Summary

• BlackRock, Inc. reported beneficial ownership of 1,245,511 shares of Artiva Biotherapeutics, Inc. Common Stock.
• This represents 5.1% of the class of securities outstanding.
• BlackRock holds sole voting power over 1,234,846 shares and sole dispositive power over 1,245,511 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• The filing was made pursuant to Rule 13d-1(b), indicating BlackRock is a passive investor.
• Several BlackRock subsidiaries are identified as entities that may beneficially own shares, including BlackRock Advisors, LLC, BlackRock Fund Advisors, BlackRock Asset Management Ireland Limited, BlackRock Institutional Trust Company, National Association, BlackRock Financial Management, Inc., and BlackRock Investment Management, LLC.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing an ownership stake. It contains factual information without expressing positive or negative sentiment about the issuer's performance or outlook.

Positives

• BlackRock, a major institutional investor, holding a 5.1% stake can be seen as a vote of confidence in Artiva Biotherapeutics.
• The filing confirms the investment is passive, reducing concerns about potential activist interventions.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Artiva Biotherapeutics, Inc.'s future performance or strategic direction. It solely reports BlackRock, Inc.'s beneficial ownership stake.

Management Comments

• "To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing indicates a significant passive investment by BlackRock, one of the world's largest asset managers, in Artiva Biotherapeutics, a company operating in the biotechnology sector. Such institutional ownership is common for publicly traded companies and reflects BlackRock's portfolio management activities rather than a specific strategic move within the biotechnology industry.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder, potentially signaling institutional confidence.
• Investment Professionals: Offers data for tracking institutional ownership and portfolio composition.

Key Dates

Keywords

Artiva Biotherapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biotechnology, Passive Investment